Consensus statement for the treatment of infantile haemangiomas with propranolol

Sarah L. Smithson, Marius Rademaker, Susan Adams, Stuart Bade, Philip Bekhor, Samantha Davidson, Amanda Dore, Catherine Drummond, Gayle Fischer, Alexander Gin, Claire Grills, Anne Halbert, Zerina Lokmic, Emma McCahon, Vanessa A. Morgan, Dedee F Murrell, David Orchard, Anthony Penington, Diana Purvis, John RelicSusan Robertson, Aaron J. Robinson, Laura Scardamaglia, John Su, Swee Tan, Orli Wargon, Lachlan Warren, Li Chuen Wong, Tania Zappala, Roderic Phillips

Research output: Contribution to journalArticleOtherpeer-review

51 Citations (Scopus)


Although most infantile haemangiomas do not require treatment due to a natural history of spontaneous involution, some require early intervention. The Australasian Vascular Anomalies Network and the Australasian Paediatric Dermatology Network have developed a consensus statement for the treatment of infantile haemangiomas with oral propranolol. Infants with haemangiomas that are life threatening, at risk of ulceration, or at risk of causing a significant functional impairment, psychological impact or physical deformity should be treated early with oral propranolol. Oral propranolol is safe and effective and in most healthy infants oral propranolol can be started in an outpatient setting.

Original languageEnglish
Pages (from-to)155-159
Number of pages5
JournalAustralasian Journal of Dermatology
Issue number2
Publication statusPublished - May 2017
Externally publishedYes


  • Australian
  • beta-blocker
  • consensus
  • hemangioma
  • infantile haemangioma
  • New Zealand
  • propranolol
  • vascular anomaly

Cite this